에이비엘바이오

298380KOSDAQ기초 의약물질 제조업

52.0 / 100

Reference Date: 2026-06-10

Financial Score22.0 / 40

News Sentiment17.0 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Plunged 26.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

ABL Bio focuses on a growth-oriented business model through technology licensing (License-out) and joint development based on its dual-antibody platform 'Grabody™'. The company addresses unmet medical needs with global technology transfer cases in areas such as ADCs and immuno-oncology therapies. Its U.S. subsidiary, NEOK Bio, manages ADC clinical trials, and cash inflows from milestone achievements in licensing agreements enhance financial stability.

Number of Employees

108people

Average Salary

125.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

—Industry Average 1.743.5Point

ROE

-23.38Industry Average -6.033.5Point

3.9x industry avg (excellent)

Debt Ratio

0.47Industry Average 6.628.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲44.3% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼1068.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -24.4% (declining, 3yr)

Detailed News Sentiment

23 totalPositive 11Neutral 8Negative 4Average Sentiment Score 67.8

Negative
코스피 7750선에서 등락…‘젠슨 황’ 수혜주는 줄줄이 급락
에이비엘바이오 주가는 코스피 하락과 관련된 시장 전반의 불안정성으로 인해 하락 추세를 보임.
Neutral
[바이오스냅] 식약처, 한국·아세안 의약품 GMP 콘퍼런스
관련성이 낮은 바이오스냅 콘퍼런스 내용으로 에이비엘바이오의 직접적인 영향은 미미함.
Positive
에이비엘바이오, 월드 ADC 코리아서 차세대 이중항체 ADC ABL20...
에이비엘바이오는 주요 ADC 전문 행사에서 ABL209 후보물질을 소개하며 기술적 우위를 강조했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 92,400Won52-week high 245,50052-week low 61,800

1-month return0.0Point

1m -26.90% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral[기재정정]투자판단관련주요경영사항(임상시험계획변경승인신청) (이중항체 면역항암제 ABL503의 제1상 임상시험계획 (IND) 변경승인 신청)2026-06-09
Neutral투자판단관련주요경영사항(임상시험계획변경승인신청) (이중항체 면역항암제 ABL503의 제1상 임상시험계획 (IND) 변경승인 신청)2026-06-04